Psyence Biomedical Ltd. Form 6-K Summary
Business Context and Reporting Period
Psyence Biomedical Ltd., an Ontario corporation and foreign private issuer filing annual reports on Form 20-F, filed this Form 6-K on June 6, 2024, for the month of June 2024. The filing reports an additional issuance under the company’s senior secured convertible debt financing.
Key Financial and Capital Structure Information
| Item | Reported information |
|---|---|
| Financing capacity | Up to $12.5 million of aggregate principal under up to four senior secured convertible notes, in exchange for up to $10.0 million of subscription amounts. |
| First tranche | $3.125 million principal issued for $2.5 million of subscription amounts in connection with the January 15, 2024 business combination closing. |
| Second tranche issued | Two notes issued May 31, 2024 for $312,500 aggregate principal in exchange for $250,000 funded by investors. |
| Interest | Second Tranche Notes accrue interest at 8.0% annually on outstanding principal, payable monthly in cash or common shares at the applicable conversion price. |
| Security | The financing is senior secured and obligations are guaranteed by certain assets of the company and an affiliate. |
| Revenue, profit, cash flow, margins and liquidity | The filing does not provide operating results, cash flow, margin data, total debt, cash balances or liquidity measures. |
Material Changes Versus the Prior Comparable Period
- The company issued a portion of the second financing tranche: $312,500 principal for $250,000 of proceeds.
- Investors were not obligated to fund the second tranche because the company was not in compliance with all covenants under the Securities Purchase Agreement. Investors nevertheless agreed to fund the reported portion and may fund additional amounts at their discretion.
- The Second Tranche Notes generally mirror the First Tranche Notes, but their conversion floor and first and second reset dates were removed because those dates had passed.
Conversion Terms, Registration and Risks
- The initial conversion price is based on the lowest daily VWAP during the specified period beginning January 25, 2024, subject to the terms of the note and applicable conversion or registration events.
- The conversion price is scheduled to reset on July 25, 2024, October 25, 2024 and January 25, 2025 to the lower of the initial conversion price or the average daily VWAP for the prior 10 trading days. These resets may increase potential equity dilution.
- Shares issuable upon conversion have registration rights. The company must file a resale registration statement and use best efforts to obtain SEC effectiveness by applicable deadlines.
- The Registration Rights Agreement includes potential penalties for failures relating to filing, effectiveness, maintenance of resale conditions or Rule 144 requirements, subject to conditions and cure periods.
- The filing does not provide a specific remediation plan for the reported covenant noncompliance or quantify any registration-related penalties.
Guidance, Outlook and Unusual Items
No revenue or earnings guidance, operating outlook, management forecast or broader business outlook is provided. The principal unusual item is the discretionary partial funding of the second tranche despite the company’s covenant noncompliance. Additional financing remains discretionary and is not assured.
Important Facts for Investors to Verify
- The company’s current covenant compliance status and whether any defaults, waivers or remedies apply.
- The amount and timing of any additional Second Tranche funding.
- The outstanding principal, accrued interest and total secured debt after the May 31 issuance.
- The applicable conversion price, future reset prices and potential dilution from note conversions or interest paid in shares.
- The filing and effectiveness status of the resale registration statement and any registration penalties.
- Current cash, liquidity, operating losses and cash-burn information, which are not included in this Form 6-K.